Wednesday, January 21, 2015 9:51:37 PM
BY AMY REEVES, INVESTOR'S BUSINESS DAILY
02:13 PM ET
As the price war over the new hepatitis C drugs heats up, the 2015 consensus estimates for both may be too high, according to Deutsche Bank.
In two separate notes Tuesday and Wednesday, analyst Robyn Karnauskas calculated the prospects for AbbVie's (NYSE:ABBV) Viekira Pak and Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi after the two companies announced a series of exclusive agreements with payers and pharmacy benefit managers.
"ABBV has so far nailed down 7% of US lives (Express Scripts (NASDAQ:ESRX) national formulary) while GILD has been chosen as preferred for 30% of US lives (CVS (NYSE:CVS) and Anthem (NYSE:ANTM)," she wrote. "If we were to assume 10% market share for ABBV among non-exclusive/preferred lives, we see overall share for ABBV at 14% and US sales at $1.25 billion in 2015."
With added revenues from Europe, where the drugs in Viekira Pak are expected to launch this year both as a set and as separate products, Karnauskas arrived at total HCV sales of $2 billion vs. $2.7 billion consensus. However, she also expects Gilead is going to low-ball consensus due to the price discounts it's had to negotiate to compete with AbbVie.
"At worst case, we expect discounts in commercial channels to be 15% for Harvoni (5% Sovaldi) which coupled with government discounts (40% Harvoni, 30% Sovaldi) calculates to 22% overall discount for HCV franchise," she wrote, explaining that this could result in revenue guidance $1 billion lower than the present consensus of $28.6 billion. "If guidance comes $2.5 billion lower that would validate what PBMs (pharmacy benefit managers) are telegraphing regarding discounts."
AbbVie is due to report Q4 and 2015 guidance on Jan. 30. Gilead hasn't yet set a date for its report.
Despite these lowered estimates, Karnauskas maintained a buy rating on both stocks due to their pipelines full of other promising drug candidates. The stocks didn't react much on the stock market today: In afternoon trading, Gilead was down 0.5% while AbbVie was down 1.4%. Gilead moved back above its 50-day moving average on Tuesday while AbbVie continues to slide below that key level.
http://news.investors.com/technology/012115-735507-hepatitis-c-drugs-gilead-abbvie-may-miss-estimates.htm
Recent ENTA News
- Enanta Pharmaceuticals to Participate in Investor Conferences in September • Business Wire • 09/03/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 09:24:47 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:05:10 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Business Wire • 08/05/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 09:29:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 12:38:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:15:05 PM
- Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/08/2024 08:37:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:00:34 PM
- Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference • Business Wire • 05/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:05:14 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Business Wire • 05/06/2024 08:01:00 PM
- Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/30/2024 11:10:00 AM
- Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer • Business Wire • 04/30/2024 11:00:00 AM
- Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 • Business Wire • 04/29/2024 11:00:00 AM
- Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 • Business Wire • 04/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:15:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:12:41 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM